Recent Updates
Recently added Catalysts
BMGL Negative Sentiment Score: 35/100

Receipt of Delinquency Notification from Nasdaq Singapore

Key Takeaway: Basel Medical Group Ltd (BMGL) has received a delinquency notification from Nasdaq due to an incomplete annual report for the fiscal year ended June 30, 2025. This notification indicates that the report lacked the required opinion from its auditor regarding the company's financial statements. The company has 60 days to submit a compliance plan, which, if accepted, may grant them an additional 180 days to rectify the issue. Meanwhile, trading of BMGL shares on Nasdaq remains unaffected by this compliance issue.

Market Sentiment Analysis

CONCERNS & RISKS

  • The company received a delinquency notification due to incomplete filing of its annual report.
  • The absence of an auditor's opinion on financial statements led to the non-compliance.
  • There is uncertainty about whether Nasdaq will approve the company's plan to regain compliance.
  • The company faces potential penalties if it fails to meet the compliance deadline.

Full Press Release Details

Receipt of Delinquency Notification from Nasdaq
Singapore, December 1, 2025 (GLOBE NEWSWIRE)
- Basel Medical Group Ltd (Nasdaq: BMGL) (the "Company"), today announced that it has received notification from
Nasdaq that the Company's annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company
is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company's auditor,
NLA DFK Assurance PAC, on the Company's financial statements. Pursuant to Listing Rule 5250(c)(1), companies shall timely file
all required periodic financial reports with the United States Securities and Exchange Commission, and annual reports filed shall contain
audited financial statements.
Under Nasdaq rules, the Company now has 60 calendar
days to submit a plan to regain compliance and if such plan is accepted by Nasdaq, an exception of up to 180 calendar days from the original
filing's due date may be granted, or until May 18, 2026, to regain compliance. In determining whether to accept such plan, Nasdaq
will consider such things as the likelihood that the filing, along with any subsequent periodic filing that will be due, can be made within
the 180 day period, the Company's past compliance history, the reasons for the late filing, other corporate events that may occur
within our review period, the Company's overall financial condition and its public disclosures. Any subsequent periodic filing that
is due within the 180 day exception period must be filed no later than the end of the period. If the plan to regain compliance is not
accepted, the Company will have the opportunity to appeal that decision to a Hearings Panel.
The Company is currently working with its accounting,
audit and legal professionals to prepare a rectification plan to remedy the above mentioned non-compliance. Trading of the Company's
shares on Nasdaq is not currently affected by such non-compliance.
About Basel Medical Group Ltd
Basel Medical is a Singapore-based provider of orthopedic
and trauma services, sports medicine, orthopedic procedures and surgery, as well as neurosurgical treatments, executive health screening
services, occupational medicine, rehabilitation, mental and women's health and general practices. Our operations are based in Singapore,
with our clinics being located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles
Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, in particular
those in the construction, marine and oil & gas industries, which underpin our robust business model. As an medical service provider
in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare
industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage,
government effort and expenditure on healthcare, growing sports participation rate and Singapore's position as a premium destination
for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists,
general practitioners, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company
of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the
Company's website: www.baselmedical.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking
statements, which involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections
about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can
find many (but not all) of these statements by the use of words such as "aim", "anticipate", "believe",
"estimate", "expect", "going forward", "intend", "may", "plan",
"potential", "predict", "propose", "seek", "should", "will", "would"
or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking
statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you
that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from
the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings
Basel Medical Group Ltd

Frequently Asked Questions

What notification did Basel Medical Group receive from Nasdaq?

The Company received notice that its annual report was incomplete and is delinquent.

Why is Basel Medical Group considered delinquent by Nasdaq?

The annual report lacked an auditor's opinion on the financial statements.

What is Basel Medical Group's timeframe to regain compliance?

The Company has 60 days to submit a compliance plan, with a possible extension.

Is the trading of Basel Medical Group's shares affected by this issue?

Currently, trading of the Company's shares on Nasdaq is not impacted.

What services does Basel Medical Group provide?

They offer orthopedic and trauma services, sports medicine, and neurosurgical treatments.

Last updated: Dec 1, 2025